| Literature DB >> 24266713 |
Kuixing Zhang1, Nilima Biswas, Jiaur R Gayen, Jose Pablo Miramontes-Gonzalez, C Makena Hightower, Maja Mustapic, Manjula Mahata, Chun-Teng Huang, Vivian Y Hook, Sushil K Mahata, Sucheta Vaingankar, Daniel T O'Connor.
Abstract
Chromogranin B (CHGB) is the major matrix protein in human catecholamine storage vesicles. CHGB genetic variation alters catecholamine secretion and blood pressure. Here, effective Chgb protein under-expression was achieved by siRNA in PC12 cells, resulting in ~ 48% fewer secretory granules on electron microscopy, diminished capacity for catecholamine uptake (by ~ 79%), and a ~ 73% decline in stores available for nicotinic cholinergic-stimulated secretion. In vivo, loss of Chgb in knockout mice resulted in a ~ 35% decline in chromaffin granule abundance and ~ 44% decline in granule diameter, accompanied by unregulated catecholamine release into plasma. Over-expression of CHGB was achieved by transduction of a CHGB-expressing lentivirus, resulting in ~ 127% elevation in CHGB protein, with ~ 122% greater abundance of secretory granules, but only ~ 14% increased uptake of catecholamines, and no effect on nicotinic-triggered secretion. Human CHGB protein and its proteolytic fragments inhibited nicotinic-stimulated catecholamine release by ~ 72%. One conserved-region CHGB peptide inhibited nicotinic-triggered secretion by up to ~ 41%, with partial blockade of cationic signal transduction. We conclude that bi-directional quantitative derangements in CHGB abundance result in profound changes in vesicular storage and release of catecholamines. When processed and released extra-cellularly, CHGB proteolytic fragments exert a feedback effect to inhibit catecholamine secretion, especially during nicotinic cholinergic stimulation.Entities:
Keywords: adrenal; catecholamines; chromaffin; chromogranin B; hypertension
Mesh:
Substances:
Year: 2013 PMID: 24266713 PMCID: PMC3992281 DOI: 10.1111/jnc.12527
Source DB: PubMed Journal: J Neurochem ISSN: 0022-3042 Impact factor: 5.372